CBC Group, a healthcare-dedicated investment firm, and Mubadala, a sovereign investor, led a $315m round in Hasten Biopharma, an innovation-driven pharmaceutical company. "Hasten is a well-established Chinese biopharma company with tremendous growth potential. The firm reported 47% growth in sales from Q2 to Q4 in 2022, which is testament to CBC's unique and effective investor-operator strategy. We are confident that the attractive entry valuation, coupled with strong operational and growth momentum, will create long-term sustainable value for CBC and our fellow shareholders," Fu Wei, CBC Group CEO.